Status and phase
Conditions
Treatments
About
A Prospective, randomized, double-blinded, placebo-controlled trial will be conducted at the pediatric dialysis unit, Children's Hospital, Ain Shams University in order to investigate the benefits of melatonin supplementation on oxidative stress, inflammation and to assess sleep quality by using PSQI questionnaire in pediatric hemodialysis patients.
Full description
1.Oxidative stress marker malondialdehyde (MDA) by ELISA assay. 2. Inflammatory marker level nuclear factor kappa B (NF-KB) by ELISA assay 3. Complete blood picture (CBC). 4. Lipid profile (total cholesterol(TC), triglycerides(TG), high-density lipoprotein (HDL) and low-density lipoprotein (LDL) 5)Safety will be assessed weekly after the beginning of the study by monitoring the side effects or any adverse drug reactions.
A total of (40) patients on regular HD will be enrolled in the study. These patients will be randomly assigned in a 1:1 ratio into two groups:
All subjects will sign an informed consent statement prior to inclusion in the study.
All subjects will be followed up weekly for 12 weeks and blood samples will be withdrawn at baseline and the end of the study.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
All patients will be assessed for eligibility according to the following inclusion and exclusion criteria:
Inclusion Criteria:
Exclusion Criteria:
Primary purpose
Allocation
Interventional model
Masking
40 participants in 2 patient groups, including a placebo group
Loading...
Central trial contact
Ghadeer Amged, BSc
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal